Published by Global Banking & Finance Review®
Posted on February 25, 2026
1 min readLast updated: April 2, 2026
Add as preferred source on GoogleOn Feb 25, 2026, EQT said it will not proceed with a takeover of Oxford Biomedica, sending OXB shares down nearly 10%. Under Rule 2.8, EQT is restricted from making another approach unless conditions change.
Feb 25 (Reuters) - Private equity group EQT said on Wednesday it had decided not to proceed with a takeover offer for Oxford Biomedica, sending the British cell and gene therapy manufacturer's shares down nearly 10%.
(Reporting by Ankita Bora in Bengaluru; Editing by Shreya Biswas)
EQT decided not to proceed with a takeover of Oxford Biomedica on Feb 25, 2026, which led to a near-10% drop in the biotech firm’s shares.
EQT issued a Rule 2.8 statement saying it does not intend to make an offer. The announcement did not disclose reasons or terms.
After a Rule 2.8 statement, EQT is generally restricted for six months from making another offer unless exceptions apply, such as a third-party bid or board consent.
Explore more articles in the Finance category
